LakeShore Biopharma
LSB was delisted on the 19th of September, 2025.
6 hedge funds and large institutions have $1.34M invested in LakeShore Biopharma in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
1.87% more ownership
Funds ownership: 0.17% → 2.04% (+1.9%)
14% less funds holding
Funds holding: 7 → 6 (-1)
40% less capital invested
Capital invested by funds: $2.23M → $1.34M (-$887K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$412K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$424K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$75.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$11.7K |
| 4 |
Barclays
London,
United Kingdom
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $486K | +$412K | +140,428 | New |
|
|
2
Fidelity Investments
Boston,
Massachusetts
| $402K | +$3 | +1 | +0% |
|
|
HA
3
HHLR Advisors
Grand Cayman,
Cayman Islands
| $259K | – | – | – |
|
|
SCM
4
Superstring Capital Management
New York
| $106K | – | – | – |
|
|
5
Barclays
London,
United Kingdom
| $85.7K | -$3 | -1 | -0% |
|
|
6
UBS Group
Zurich,
Switzerland
| $3.25K | -$11.7K | -4,002 | -81% |
|
|
7
Fidelity International
Hamilton,
Bermuda
| – | -$424K | -61,548 | Closed |
|
|
8
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$75.5K | -9,381 | Closed |
|
LSB Hedge Fund Activity: Q4 2024 in Review
6 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q4 2024, worth a combined $1.34M — down 40% from $2.23M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LSB and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $412K. The largest seller was Fidelity International, exiting entirely with an estimated $424K sold.
- 6 institutional investors held LakeShore Biopharma (LSB) as of Q4 2024, down from 7 in Q3 2024.
- Funds reported $1.34M of LakeShore Biopharma stock for Q4 2024, down 40% quarter-over-quarter.
- 1 fund opened new LakeShore Biopharma positions in Q4 2024 and 2 closed out, a net change of -1 holder.
- The largest LakeShore Biopharma buyer in Q4 2024 was OrbiMed, an estimated $412K added.
- The largest LakeShore Biopharma seller in Q4 2024 was Fidelity International, an estimated $424K sold.
Based on aggregated 13F filings for Q4 2024.